Delivery Order SPE2DB20D9329-SPE2DB25FZK99
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $25,868.10 by the Defense Logistics Agency for the supply of Xtandi 40 mg capsules (120-count units). The contract is firm fixed-price with an ultimate completion date of September 2, 2025, and carries no set-aside designation. This delivery order represents one of numerous pharmaceutical supply contracts issued to DMS Pharmaceutical Group...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency on August 25, 2025, for the supply of Xtandi 40 mg capsules (120-count). The contract carries no set-aside designation and is scheduled for completion by August 26, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 10, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract ceiling value is $38,376.87, with an ultimate completion date of September 11, 2025. This delivery order carries no set-aside designation and represents a direct fulfillment order under DMS Pharmaceutical...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,622.72 by the Defense Logistics Agency (DLA) on June 5, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is scheduled for ultimate completion by June 6, 2025, with performance taking place at the vendor's Park Ridge facility. This delivery order was...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $43,113.50 by the Defense Logistics Agency on August 20, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of August 21, 2025, and no set-aside designation was used in the award. Performance will occur at the contractor's facility in Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 4, 2025, for the supply of Xtandi 40 mg capsules (120-count units) with a ceiling value of $17,245.40. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 5, 2025. This award carries no set-aside designation, demonstrating the company's competitive...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $8,339.18 by the Defense Logistics Agency on July 21, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This delivery order was issued without a set-aside designation and is scheduled for completion by July 22, 2025, with performance taking place at the contractor's Park Ridge facility. The award represents a...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,311.35 by the Defense Logistics Agency (DLA) on September 16, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract utilizes a firm fixed-price delivery order structure with an ultimate completion date of September 17, 2025. This award was made without a set-aside designation, allowing DMS Pharmaceutical Group to...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $4,565.70 for Xtandi 40mg capsules (120 count) by the Defense Logistics Agency's Medical Supply Chain on September 13, 2025. This firm fixed-price delivery order carries no set-aside designation and is being performed at the awardee's Park Ridge location. The award represents a single delivery order under DMS Pharmaceutical Group's larger...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $8,339.18 by the Defense Logistics Agency (DLA) on July 24, 2025, for the supply of Xtandi 80 mg tablets (60-count units). The contract is a firm fixed-price delivery order with an ultimate completion date of July 25, 2025, and carries no set-aside designation. This award was issued under DMS Pharmaceutical Group's larger Indefinite...
- SPE2DB20D9329Indefinite Delivery Contract
- SPE2DB20D9329-SPE2DB25FZK99Delivery Order
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $8,622.72 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). The contract, which carries no set-aside designation, is set for ultimate completion by September 4, 2025, and represents a delivery order issued under DMS Pharmaceutical Group's substantial Indefinite Delivery Contract with DLA valued at $499.9 million through November 2026. This IDC vehicle enables DLA to procure a comprehensive range of pharmaceutical products, including branded and generic prescription drugs, biologics, and medical consumables to support military health facility operations worldwide. As a critical supplier within the federal pharmaceutical supply chain, DMS Pharmaceutical Group leverages its established relationships with the DLA to distribute specialty medications including oncology treatments such as Xtandi, directly to Department of Defense healthcare facilities. The company's consistent track record of pharmaceutical delivery orders under firm fixed-price arrangements demonstrates its capability to meet federal government medical supply requirements efficiently. Xtandi, an advanced prostate cancer treatment, represents the type of specialized pharmaceutical product that supports the DLA's mission to sustain military healthcare operations across the globe.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $8.6k | 9/3/25 |